Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    52,086.75
    +896.82 (+1.75%)
     

  • CMC Crypto 200

    1,384.86
    +72.23 (+5.50%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

AstraZeneca hits 2014 Pfizer bid price, helped by Bristol's woes

Reuters - UK Focus

By Ben Hirschler

LONDON, Aug 5 (Reuters) - AstraZeneca (NYSE: AZN - news) shares hit a record high on Friday, breaching for the first time the 55 pounds a share level offered by Pfizer (NYSE: PFE - news) in 2014 during the U.S (Other OTC: UBGXF - news) . group's abortive $100 billion attempt to buy the drugmaker.

The British firm's stock has been on a roll recently, helped by a falling pound and speculation that Switzerland's Novartis might be next to launch a bid. However, the shares were lifted to a high of 55.05 pounds by the misfortunes of Bristol-Myers Squibb.

The failure of Bristol's immunotherapy drug Opdivo to slow disease progression in previously untreated patients with lung cancer as hoped was seen by investors as good news for rivals Merck (Jakarta: 28586808.JK - news) & Co and AstraZeneca.

ADVERTISEMENT

Analysts at Leerink, Jefferies and Deutsche Bank (LSE: 0H7D.L - news) said the negative result with Opdivo increased the potential market opportunity for AstraZeneca's keenly watched combination of durvalumab and tremelimumab.

Crucial clinical trial results with durvalumab, both on its own and in combination with tremelimumab, are due next year.

Chief Executive Pascal Soriot believes AstraZeneca can become a major player in cancer drugs that bolster the immune system. And its ability to carve out billions of dollars in potential sales hinges not only on the effectiveness of its own products but on the competitive profile of rivals.

Cancer is currently the hottest area of research across the drugs industry and some analysts believe this could make AstraZeneca a takeover target once again, with speculation turning last week to Novartis (LSE: 0QLR.L - news) as a bidder. (Editing by Dale Hudson)